Vaccine Info

FluMist Quadrivalent Influenza Vaccine

Authored by
Staff
Last reviewed
February 11, 2021

Flumist Quadrivalent Influenza Description

FluMist Quadrivalent is an Intranasal vaccine that is a live quadrivalent vaccine formulated to contain four vaccine virus strains.

Like other live vaccines, like the chickenpox vaccine, FluMist Quadrivalent contains a weakened live virus. The weakened live virus is designed not to cause the flu but to help protect you from the flu.

FluMist Quadrivalent triggers an immune response in the nose—the place where you usually catch the flu. It then triggers your immune system to build defenses (called antibodies), mainly in the nose where the virus enters the body.

For 2020-2021, Quadrivalent (four-component) egg-based vaccines are recommended to contain: A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus (updated); A/Hong Kong/2671/2019 (H3N2)-like virus (updated); B/Washington/02/2019 (B/Victoria lineage)-like virus (updated); /Phuket/3073/2013-like (Yamagata lineage) virus.

FluMist Quadrivalent Influenza Indication

The nasal spray flu vaccine is approved for healthy non-pregnant individuals, 2 years through 49 years old. People with certain medical conditions should not receive the nasal spray flu vaccine, says the U.S. CDC.

It works in 3 ways—in your nose, your cells, and your bloodstream—to help provide flu protection. Like the flu shot, immunity occurs within 14 days.

You should not get FluMist Quadrivalent if you have a severe allergy to eggs or any inactive ingredient in the vaccine; have ever had a life-threatening reaction to influenza vaccinations, or are 2 through 17 years old and take aspirin or medicines containing aspirin—children or adolescents should not be given aspirin for 4 weeks after getting FluMist Quadrivalent unless your healthcare provider tells you otherwise.

LAIV is not recommended for people with some chronic health conditions because this vaccine's safety and effectiveness in people with those conditions have not been established.

Children under 2 years old have an increased risk of wheezing (difficulty with breathing) after getting FluMist Quadrivalent.

Pregnant and postpartum women do not need to avoid contact with persons recently vaccinated with the nasal spray flu vaccine. However, the nasal spray flu vaccine should not be given to pregnant women. Postpartum women can receive a flu shot or the nasal spray flu vaccine.

Breastfeeding mothers younger than 50 years can get the nasal spray flu vaccine as long as they do not have a contraindication to getting that vaccine.

FluMist Quadrivalent Influenza Dosage

FluMist Quadrivalent is a vaccine sprayed into the nose by a healthcare professional.

One spray of FluMist in each nostril can help protect eligible children and adults ages 2-49. People 9 years of age and older need one dose of FluMist Quadrivalent each year. Children 2 through 8 years old may need 2 doses of FluMist Quadrivalent, depending on their history of previous influenza vaccination. Your healthcare provider will decide if your child needs to come back for a second dose.

You can breathe normally while you get FluMist Quadrivalent. It's okay if you sneeze, blow your nose, feel dripping down your nose or throat, or swallow after receiving FluMist Quadrivalent. You still get enough FluMist Quadrivalent to help protect you against the flu.

Flumist Quadrivalent Influenza News

February 11, 2021 - AstraZeneca plc published financial results, which stated Flumist Total Revenue, entirely comprising Product Sales, increased by 161% in the year (153% at CER) to $295m, reflecting the greater use of influenza vaccines as health authorities in northern-hemisphere countries expanded seasonal-vaccination programs beyond typical levels during the ongoing COVID-19 pandemic. In the US, sales increased by 254% in the year to $70m and, in Europe, by 135% (126% at CER) to $219m.

November 25, 2020 -  Israel has ordered AstraZeneca's FluMist vaccines for its citizens.

August 21, 2020 - Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — the United States, 2020–21 Influenza Season.

August 13, 2020 - AstraZeneca Ships FLUMIST® QUADRIVALENT Vaccine in the US for 2020-2021 Flu Season.  AstraZeneca has increased production of FluMist QUADRIVALENT doses in the US by over 25% more than previously planned, a majority of which are expected to be available by the end of September.

Clinical Trials

No clinical trials found